MiR-130a-3p regulates cell migration and invasion via inhibition of Smad4 in gemcitabine resistant hepatoma cells
- Yang Liu†1,
- Yumei Li†1,
- Rui Wang†1,
- Shukui Qin2,
- Jing Liu1,
- Fang Su1,
- Yan Yang1,
- Fuyou Zhao1,
- Zishu Wang1 and
- Qiong Wu1Email author
© Liu et al. 2016
Received: 20 October 2015
Accepted: 21 January 2016
Published: 27 January 2016
Emerging evidence demonstrates that microRNAs (miRNAs) play an important role in regulation of cell growth, invasion and metastasis through inhibiting the expression of their targets. It has been reported that miR-130a-3p controls cell growth, migration and invasion in a variety of cancer cells. However, it is unclear whether miR-130a-3p regulates epithelial-mesenchymal transition (EMT) in drug resistant cancer cells. Therefore, in the current study, we explore the role and molecular mechanisms of miR-130a-3p in gemcitabine resistant (GR) hepatocellular carcinoma (HCC) cells.
The real-time RT-PCR was used to measure the miR-130a-3p expression in GR HCC cells compared with their parental cells. The wound healing assay was conducted to determine the cell migratory activity in GR HCC cells treated with miR-130a-3p mimics. The migration and invasion assays were also performed to explore the role of miR-130a-3p in GR HCC cells. Western blotting analysis was used to measure the expression of Smad4, E-cadherin, Vimentin, and MMP-2 in GR HCC cells after depletion of Smad4. The luciferase assay was conducted to validate whether Smad4 is a target of miR-130a-3p. The student t-test was used to analyze our data.
We found the down-regulation of miR-130a-3p in GR HCC cells. Moreover, we validate the Smad4 as a potential target of miR-130a-3p. Furthermore, overexpression of miR-130a-3p suppressed Smad4 expression, whereas inhibition of miR-130a-3p increased Smad4 expression. Consistently, overexpression of miR-130a-3p or down-regulation of Smad4 suppressed the cell detachment, attachment, migration, and invasion in GR HCC cells.
Our findings provide a molecular insight on understanding drug resistance in HCC cells. Therefore, activation of miR-130a-3p or inactivation of Smad4 could be a novel approach for the treatment of HCC.
KeywordsHepatocellular carcinoma EMT Smad4 miR-130a-3p Invasion
Liver cancer is one of the most frequently diagnosed cancers in the United States . An estimated 35,660 new cases and 24,550 cancer deaths will be occurred from liver cancer in 2015 in the US . It has been reported that 782,500 new liver cancer cases and 745,500 deaths occurred worldwide during 2012, and half of the total number of cases and deaths are from China . Most primary liver cancers are hepatocellular carcinoma (HCC). The some factors have been reported to contribute to HCC, such as aflatoxin, chronic hepatitis B virus infection, obesity, type 2 diabetes, heavy alcohol consumption, and smoking [3, 4]. The treatments for HCC include surgical resection, liver transplantation and ablation, and chemotherapy. Since most HCC patients are diagnosed at the advanced stages, systemic chemotherapy is required. However, HCC patients often acquire drug resistance to chemotherapy, leading to limited survival benefits, suggesting that understanding and overcoming drug resistance is necessary to improve the treatment of HCC.
It has been known that miRNAs exert their regulatory functions through binding to the 3′ untranslated region (3′UTR) of target mRNA, leading to the degradation of the mRNA or translational inhibition of functional proteins. Emerging evidence has demonstrated that miRNAs are critically involved in the development and progression of human cancers including HCC [5–7]. For example, miR-93 promotes cell proliferation via targeting PTEN in osteosarcoma cells . One study showed that miR-106b promotes colorectal cancer cell migration and invasion through directly targeting DLC1 . Recently, a growing body of data implicates that micorRNAs (miRNAs) play an essential role in drug resistance through inhibition of its downstream targets in human cancers [8, 9]. For example, upregulated miR-182 increases drug resistance in cisplatin-treated HCC cells through regulation of TP53INP1 . Furthermore, miR-340 reversed cisplatin resistance of HCC cell lines via regulating Nrf2-dependent antioxidant pathway . Liu et al. found that miR-222 regulates sorafenib resistance and enhances tumorigenicity in HCC through governing PI3K/Akt pathway . Another study revealed that restoration of miR-193b sensitizes HBV-associated HCC cells to sorafenib . Moreover, reprogramming using miR-302 improves drug sensitivity in HCC cells through down-regulation of AOF2, which caused H3K4 methylation and c-Myc repression . Yang et al. found that miR-223 modulated multidrug resistance by downregulation of ABCB1 in HCC cells . Emerging evidence has also suggested that miR-338-3p , let-7b , miR-942 , miR-612 , miR-21 , miR-26b , miR-34a , miR-216a/217 , miR-193a-3p [24, 25], and miR-122 [26, 27] are critically involved in drug resistance in HCC cells. These reports define that targeting miRNAs could be a promising approach to overcome drug resistance.
Early studies reported that miR-130a was directly involved in the development of chemoresistance [28–30]. Down-regulation of miR-130a was found in a panel of paclitaxel- and cisplatin-resistant ovarian cancer cells [28, 31], gefitinib-resistant non-small cell lung cancer (NSCLC) cells , and paclitaxel-resistant prostate cancer cells . Consistently, docetaxel-resistant head and neck squamous cell carcinoma cell lines have lower expression of miR-130a-3p compared with their parental cells . Moreover, it has been reported that miR-130a targets MET and induces TRAIL-sensitivity in NSCLC cells . Furthermore, one study showed that miR-130a was down-regulated in triple-negative breast cancer, which is associated with chemoresistance . Interestingly, miR-130a was found to be upregulated in cisplatin-resistant ovarian cancer cells [35, 36]. Although these studies indicated miR-130a as a key role in chemoresistance in human cancer cells, the molecular mechanism of miR-130a-meidated drug resistance has not been fully elucidated. Therefore, the goal of this study was to explore the role of miR-130a-3p in gemcitabine resistant (GR) hepatocellular carcinoma (HCC) cells. We found the down-regulation of miR-130a-3p in GR HCC cells. More importantly, Smad4 was validated as a potential target of miR-130a-3p. Notably, overexpression of miR-130a-3p suppressed the cell migration, and invasion in GR HCC cells partly through down-regulation of Smad4. Our findings suggest that activation of miR-130a-3p or inactivation of Smad4 could be a novel approach for the treatment of HCC.
Cell culture, reagents and antibodies
HepG2, HepG2 GR, SMMC-7721, SMMC-7721 GR cells were cultured at 37 °C in 5 % CO2 in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Gaithersburg, MD, USA) supplemented with 10 % fetal bovine serum. The secondary antibodies and primary antibodies against Smad4, MMP2 and GAPDH were bought from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-Vimentin, anti-E-cadherin antibodies were obtained from Abcam.
Wound healing assay
The HCC cells and HCC GR cells were seeded in 6-well plate until the cells grew to 90–95 % confluency. The scratch wound was generated in the surface of the plates using a pipette tip in cells with miR-130a-3p mimic transfection or Smad4 siRNA treatment. Photographic images were taken from HCC and HCC GR cells at 0 and 20 h.
Cell attachment and detachment assay
Cell attachment and detachment assays were conducted as described before [37–39]. Briefly, for attachment assay, HCC GR cells transfected with Smad4 siRNA or miR-130a-3p mimics were seeded in 24-well plates at 5 × 104 cells per well. Unattached cells were removed after 1 h incubation, and the attached cells were counted after trypsinization. The data were presented as a percentage of the attached cells compared to total cells. For cell detachment assay, after 24 h incubation, the cells were incubated with 0.05 % trypsin for 3 min to detach the cells. Then, the culture medium was added to inactivate the trypsin and the detached cells were collected. The remaining cells were incubated with 0.25 % trypsin to detach and counted. The data were presented as a percentage of the detached cells to total cells.
Transwell migration and invasion assays
The migration of HCC cells was conducted using a 24-well Transwell chamber (Corning) with gelatin-coated polycarbonate membrane filter. The invasive capacity of HCC cells was performed using Transwell inserts with Matrigel (BD Biosciences). After incubation for 20 h, the upper surfaces of the Transwell chambers were scraped with cotton swabs, and the migrated and invaded cells were fixed with 4 % paraformaldehyde, and then stained with Giemsa solution. The stained cells were photographed and counted under a light microscope in five randomly-selected fields.
RNA extraction and reverse transcription-PCR analysis for gene expression
The total RNA from HCC cells and HCC GR cells was isolated with Trizol (Invitrogen) and purified with RNeasy Mini Kit and RNase-free DNase Set (Qiagen) according to the manufacturer’s protocols. The primer sequences for target genes were as follows: Smad4 (forward, 5′-CGG ACA TTA CTG GCC TGT TC-3′; reverse, 5′-TAG GGC AGC TTG AAG GAA ACC-3′; E-cadherin (forward, 5′-GAA GTG TCC GAG GAC TTT GG -3′; reverse, 5′-CAG TGT CTC TCC AAA TCC GAT A -3′); MMP-2 (forward, 5′-TAT GGC TTC TGC CCT GAG AC -3′; reverse, 5′-CAC ACC ACA TCT TTC CGT CA -3′); Vimentin (forward, 5′-TGT CCA AAT CGA TGT GGA TGT TTC-3′; reverse, 5′-TTG TAC CAT TCT TCT GCC TCC TG-3′); GAPDH (forward, 5′-CAG CCT CAA GAT CAT CAG CA -3′; reverse, 5′-TGT GGT CAT GAG TCC TTC CA-3′). The expression of GAPDH was used as internal control. RT-PCR amplifications were performed as described before .
Protein extraction and Western blotting
Cells were harvested and lysed with RIPA buffer (1 × PBS, 1 % Nonidet P40, 0.5 % sodium deoxycholate, 0.1 % SDS, and protease inhibitor cocktail). The protein concentrations were measured using the Bio-Rad protein assay kit (Bio-Rad Laboratories, CA). Immunoblotting was conducted with standard protocols as described previously .
miRNA real-time RT-PCR
The miRNA real-time RT-PCR assay was performed using miR-130a-3p TaqMan MicroRNA Assay Kit (Applied Biosystems). Briefly, ten nanogram of total RNA was reverse transcribed into cDNA and then real-time PCR was performed using specific primers for miR-130a-3p as described previously . U6 was used as an endogenous control for normalization.
Cells were seeded in six-well plates and transfected with different Smad4 siRNAs (Genepharma, Shanghai, China), miR-130a-3p mimics and miR-130a-3p inhibitors (Genepharma, Shanghai, China) using Lipofectamine 2000 as described earlier . After the indicated periods of incubation, the cells were subjected to further analysis as presented under the results section.
The wild-type and mutant Smad4 3′-UTR were amplified by PCR and cloned in pMIR-REPORT (Ambion) with firefly luciferase. A total of 5 × 104 cells treated with control, miR-130a-3p mimics, or miR-130a-3p inhibitors were transfected with wild-type or mutants of Smad4 3′ UTR luciferase reporters together with Renilla plasmid. After 48 h of transfection, the firefly and Renilla luciferase were measured according to the manufacturer’s protocols (Promega). The firefly luciferase activities were normalized to Renilla luciferase activities.
All experiments were repeated at least 3 times. Values were shown as means ± SEM and analyzed using GraphPad Prism 4.0 (Graph pad Software, La Jolla, CA). Statistical comparisons between different groups were performed using Student t test. P < 0.05 was considered statistically significant.
Down-regulation of miR-130a-3p in HCC GR cells
Smad4 is negatively associated with miR-130a-3p expression
Smad4 is a downstream target of miR-130a-3p
Bioinformatics analysis indicated that the Smad4 3′UTR harbors potential miR-130a-3p target sites (Fig. 3b). To further verify the Smad4 as a potential target of miR-130a-3p, we conducted the reporter assay in HCC cells with the luciferase gene driven by either wild-type or mutated Smad4 3′UTR sequences. We found that it has a significant reduction in luciferase activity with wild-type Smad4, but not mutant Smad4, in HepG2 GR cells transfected with miR-130a-3p mimic (Fig. 3b). Consistently, miR-130a-3p inhibitors treatment led to increased luciferase activity with wild-type Smad4 in HepG2 cells (Fig. 3b). Taken together, these findings further validate that Smad4 is a downstream target of miR-130a-3p.
Down-regulation of Smad4 reverses EMT to MET in HCC GR cells
Depletion of Smad4 regulated EMT markers in HCC GR cells
To further confirm the reversal of EMT by knockdown of Smad4 in HCC GR cells, we detected the expression of EMT molecular markers. Our RT-PCR results showed that depletion of Smad4 decreased E-cadherin mRNA, but increased Vimentin and MMP2 mRNA levels in HepG2 GR and SMMC 7721 GR cells (Fig. 4c). Consistently, the results from our Western blotting validated that E-cadherin was increased, while Vimentin and MMP2 are down-regulated after depletion of Smad4 in HepG2 GR and SMMC 7721 GR cells (Fig. 4d). These results suggest that down-regulation of Smad4 caused the reversal of EMT to MET phenotype.
Down-regulation of Smad4 inhibited cell migration and invasion in HCC GR cells
Over-expression of miR-130a-3p enhances GR cells to gemcitabine sensitivity
Recent studies have highlighted the important role of miR-130a in HCC progression and metastasis [45–47]. One study showed that miR-130a regulated the HBV-associated estrogen receptor alpha in human HCC cells . miR-130a expression is correlated with pathological tumor grade in HCC . Li et al. found that miR-130a expression was significantly down-regulated in HCC . Moreover, lower expression of miR-130a was associated with overall survival of patients with HCC , suggesting that miR-130a could serve as a potential prognostic biomarker for HCC patients. Remarkably, it has been discovered that upregulated miR-130a increased drug resistance by targeting RUNX3 and Wnt signaling in cisplatin-treated HCC cells . Our current study revealed that miR-130a-3p was down-regulated in HCC GR cells and overexpression of miR-130a-3p inhibited cell migration and invasion.
The data presented here demonstrated that miR-130a-3p-regulated EMT and cell invasion through inhibition of Smad4 in HCC GR cells. Recent studies have identified critical roles of Smad4 in tumorigenesis and EMT processes [50, 51]. Some studies have demonstrated that Smad4 plays tumor suppressive functions in most types of human cancers [52, 53]. However, multiple studies have indicated that Smad4 has oncogenic functions in several kinds of human cancers . It is clear that Smad4 exerts a tumor-promoting role in HCC. Specifically, knockdown of Smad4 significantly reduced the colony formation and migratory capacity of HCC cells . Moreover, overexpression of Smad4 was observed in HCC patient tumors compared with adjacent tissues . Furthermore, knockdown of Smad4 significantly increased E-cadherin expression in prostate cancer cells . Qiao et al. reported that miR-34a inhibited EMT in human cholangiocarcinoma by targeting Smad4 via TGF-beta/Smad signaling pathway . In line with these findings, our results showed that knockdown of Smad4 inhibits cell migration, and invasion in HCC GR cells. Altogether, inactivation of Smad4 could be a novel strategy for the treatment of HCC.
A number of observations demonstrated that some small molecules and natural compounds could regulate the expression of miRNAs [55–57]. Multimodal synthetic small molecules have been developed to target the production of oncognic miRNAs . Arsenic trioxide has been discovered to down-regulate miR-125b expression in huma glioma . More importantly, natural compound curcumin has been reported to modulate miR-203-mediated regulation of the Src-Akt axis in bladder cancer . Similarly, genistein inhibited cell growth and invasion via regulation of miR-27a and miR-34a in pancreatic cancer cells [58, 59]. Therefore, it is required to develop small molecules and discover compounds to control the expression of miRNAs in the near future. To this end, we found for the first time that miR-130a-3p was decreased in HCC GR cells. Moreover, we validated that miR-130a-3p targeted Smad4 expression. Notably, we confirmed that Smad4 plays a critical role in regulation of migration and invasion and EMT in HCC GR cells. Strikingly, reintroduction of miR-130a-3p enhances GR cells to gemcitabine sensitivity. However, transfection of mutant Smad4 without a miR-130a-3p binding site in HepG2 cells led to gemcitabine resistance (data not shown), suggesting that Smad4 plays a critical role in miR-130a-3p-mediated gemcitabine sensitivity. Altogether, our findings provide an insight into the molecular basis involved in gemcitabine resistance. However, further exploration is necessary to fully understand the molecular insights on miR-130a-mediated drug resistance and EMT in HCC cells.
In summary, our study describes a potential mechanism for dysregulation of Smad4 by miR-130a-3p in HCC. Taken together, upregulation of miR-130a-3p and inactivation of Smad4 could be a promising approach for achieving better treatment of HCC.
This work was supported by funding from the National Natural Sciences Fund Youth Fund (81402036), the Anhui Provincial Natural Science Foundation (1508085MH197), the Natural Science Research key Project of Education Office of Anhui Province (KJ2014A152), and the Bengbu Medical College Research and Innovation Program (Byycx1425).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.View ArticlePubMedGoogle Scholar
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.View ArticlePubMedGoogle Scholar
- El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–27.View ArticlePubMedGoogle Scholar
- Mileo AM, Mattarocci S, Matarrese P, Anticoli S, Abbruzzese C, Catone S, et al. Hepatitis C virus core protein modulates pRb2/p130 expression in human hepatocellular carcinoma cell lines through promoter methylation. J Exp Clin Cancer Res. 2015;34:140.PubMed CentralView ArticlePubMedGoogle Scholar
- Kawano M, Tanaka K, Itonaga I, Ikeda S, Iwasaki T, Tsumura H. microRNA-93 promotes cell proliferation via targeting of PTEN in Osteosarcoma cells. J Exp Clin Cancer Res. 2015;34:76.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhang GJ, Li JS, Zhou H, Xiao HX, Li Y, Zhou T. MicroRNA-106b promotes colorectal cancer cell migration and invasion by directly targeting DLC1. J Exp Clin Cancer Res. 2015;34:73.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang H, Guan X, Tu Y, Zheng S, Long J, Li S, et al. MicroRNA-29b attenuates non-small cell lung cancer metastasis by targeting matrix metalloproteinase 2 and PTEN. J Exp Clin Cancer Res. 2015;34:59.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, Banerjee S, et al. Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist Updat. 2010;13:109–18.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhou Y, Huang Z, Wu S, Zang X, Liu M, Shi J. miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST. J Exp Clin Cancer Res. 2014;33:12.PubMed CentralView ArticlePubMedGoogle Scholar
- Qin J, Luo M, Qian H, Chen W. Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1. Gene. 2014;538:342–7.View ArticlePubMedGoogle Scholar
- Shi L, Chen ZG, Wu LL, Zheng JJ, Yang JR, Chen XF, et al. miR-340 reverses cisplatin resistance of hepatocellular carcinoma cell lines by targeting Nrf2-dependent antioxidant pathway. Asian Pac J Cancer Prev. 2014;15:10439–44.View ArticlePubMedGoogle Scholar
- Liu K, Liu S, Zhang W, Ji B, Wang Y, Liu Y. miR222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma. Int J Oncol. 2014;45:1537–46.PubMedGoogle Scholar
- Mao K, Zhang J, He C, Xu K, Liu J, Sun J, et al. Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib. Cancer Lett. 2014;352:245–52.View ArticlePubMedGoogle Scholar
- Koga C, Kobayashi S, Nagano H, Tomimaru Y, Hama N, Wada H, et al. Reprogramming using microRNA-302 improves drug sensitivity in hepatocellular carcinoma cells. Ann Surg Oncol. 2014;21 Suppl 4:S591–600.View ArticlePubMedGoogle Scholar
- Yang T, Zheng ZM, Li XN, Li ZF, Wang Y, Geng YF, et al. MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells. Exp Biol Med (Maywood). 2013;238:1024–32.View ArticleGoogle Scholar
- Xu H, Zhao L, Fang Q, Sun J, Zhang S, Zhan C, et al. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1alpha. PLoS One. 2014;9:e115565.PubMed CentralView ArticlePubMedGoogle Scholar
- Ma J, Guo R, Wang T, Pan X, Lei X. Let-7b binding site polymorphism in the B-cell lymphoma-extra large 3′UTR is associated with fluorouracil resistance of hepatocellular carcinoma. Mol Med Rep. 2015;11:677–81.PubMedGoogle Scholar
- Liu N, Zuo C, Wang X, Chen T, Yang D, Wang J, et al. miR-942 decreases TRAIL-induced apoptosis through ISG12a downregulation and is regulated by AKT. Oncotarget. 2014;5:4959–71.PubMed CentralView ArticlePubMedGoogle Scholar
- Tang J, Tao ZH, Wen D, Wan JL, Liu DL, Zhang S, et al. MiR-612 suppresses the stemness of liver cancer via Wnt/beta-catenin signaling. Biochem Biophys Res Commun. 2014;447:210–5.View ArticlePubMedGoogle Scholar
- Tomimaru Y, Eguchi H, Nagano H, Wada H, Tomokuni A, Kobayashi S, et al. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-alpha/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer. 2010;103:1617–26.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhao N, Wang R, Zhou L, Zhu Y, Gong J, Zhuang SM. MicroRNA-26b suppresses the NF-kappaB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3. Mol Cancer. 2014;13:35.PubMed CentralView ArticlePubMedGoogle Scholar
- Yang F, Li QJ, Gong ZB, Zhou L, You N, Wang S, et al. MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment. Technol Cancer Res Treat. 2014;13:77–86.PubMedGoogle Scholar
- Xia H, Ooi LL, Hui KM. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology. 2013;58:629–41.View ArticlePubMedGoogle Scholar
- Ma K, He Y, Zhang H, Fei Q, Niu D, Wang D, et al. DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression. J Biol Chem. 2012;287:5639–49.PubMed CentralView ArticlePubMedGoogle Scholar
- Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL, et al. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2010;70:5184–93.View ArticlePubMedGoogle Scholar
- Xu Y, Xia F, Ma L, Shan J, Shen J, Yang Z, et al. MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett. 2011;310:160–9.PubMedGoogle Scholar
- Yang F, Zhang L, Wang F, Wang Y, Huo XS, Yin YX, et al. Modulation of the unfolded protein response is the core of microRNA-122-involved sensitivity to chemotherapy in hepatocellular carcinoma. Neoplasia. 2011;13:590–600.PubMed CentralView ArticlePubMedGoogle Scholar
- Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 2008;111:478–86.View ArticlePubMedGoogle Scholar
- Dai Y, Xie CH, Neis JP, Fan CY, Vural E, Spring PM. MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck. 2011;33:786–91.View ArticlePubMedGoogle Scholar
- Acunzo M, Visone R, Romano G, Veronese A, Lovat F, Palmieri D, et al. miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene. 2012;31:634–42.PubMed CentralPubMedGoogle Scholar
- Zhang X, Huang L, Zhao Y, Tan W. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly. Acta Biochim Biophys Sin (Shanghai). 2013;45:995–1001.View ArticleGoogle Scholar
- Zhou YM, Liu J, Sun W. MiR-130a overcomes gefitinib resistance by targeting met in non-small cell lung cancer cell lines. Asian Pac J Cancer Prev. 2014;15:1391–6.View ArticlePubMedGoogle Scholar
- Fujita Y, Kojima T, Kawakami K, Mizutani K, Kato T, Deguchi T, et al. miR-130a activates apoptotic signaling through activation of caspase-8 in taxane-resistant prostate cancer cells. Prostate. 2015;75:1568–78.View ArticlePubMedGoogle Scholar
- Ouyang M, Li Y, Ye S, Ma J, Lu L, Lv W, et al. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. PLoS One. 2014;9:e96228.PubMed CentralView ArticlePubMedGoogle Scholar
- Yang L, Li N, Wang H, Jia X, Wang X, Luo J. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance. Oncol Rep. 2012;28:592–600.PubMedGoogle Scholar
- Li N, Yang L, Wang H, Yi T, Jia X, Chen C, et al. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells. PLoS One. 2015;10:e0128886.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang R, Li Y, Hou Y, Yang Q, Chen S, Wang X, et al. The PDGF-D/miR-106a/Twist1 pathway orchestrates epithelial-mesenchymal transition in gemcitabine resistance hepatoma cells. Oncotarget. 2015;6:7000–10.PubMed CentralView ArticlePubMedGoogle Scholar
- Kong D, Wang Z, Sarkar SH, Li Y, Banerjee S, Saliganan A, et al. Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells. Stem Cells. 2008;26:1425–35.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009;69:2400–7.PubMed CentralView ArticlePubMedGoogle Scholar
- Wu Q, Wang R, Yang Q, Hou X, Chen S, Hou Y, et al. Chemoresistance to gemcitabine in hepatoma cells induces epithelial-mesenchymal transition and involves activation of PDGF-D pathway. Oncotarget. 2013;4:1999–2009.PubMed CentralView ArticlePubMedGoogle Scholar
- Yang Q, Huang J, Wu Q, Cai Y, Zhu L, Lu X, et al. Acquisition of epithelial-mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells. Br J Cancer. 2014;110:1958–67.PubMed CentralView ArticlePubMedGoogle Scholar
- Pan Y, Wang R, Zhang F, Chen Y, Lv Q, Long G, et al. MicroRNA-130a inhibits cell proliferation, invasion and migration in human breast cancer by targeting the RAB5A. Int J Clin Exp Pathol. 2015;8:384–93.PubMed CentralPubMedGoogle Scholar
- Hager M, Pedersen CC, Larsen MT, Andersen MK, Hother C, Gronbaek K, et al. MicroRNA-130a-mediated down-regulation of Smad4 contributes to reduced sensitivity to TGF-beta1 stimulation in granulocytic precursors. Blood. 2011;118:6649–59.View ArticlePubMedGoogle Scholar
- Zumbrennen-Bullough KB, Wu Q, Core AB, Canali S, Chen W, Theurl I, et al. MicroRNA-130a is up-regulated in mouse liver by iron deficiency and targets the bone morphogenetic protein (BMP) receptor ALK2 to attenuate BMP signaling and hepcidin transcription. J Biol Chem. 2014;289:23796–808.PubMed CentralView ArticlePubMedGoogle Scholar
- Li B, Huang P, Qiu J, Liao Y, Hong J, Yuan Y. MicroRNA-130a is down-regulated in hepatocellular carcinoma and associates with poor prognosis. Med Oncol. 2014;31:230.View ArticlePubMedGoogle Scholar
- Motawi TK, Shaker OG, El-Maraghy SA, Senousy MA. Serum MicroRNAs as Potential Biomarkers for Early Diagnosis of Hepatitis C Virus-Related Hepatocellular Carcinoma in Egyptian Patients. PLoS One. 2015;10:e0137706.PubMed CentralView ArticlePubMedGoogle Scholar
- Xu N, Shen C, Luo Y, Xia L, Xue F, Xia Q, et al. Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell. Biochem Biophys Res Commun. 2012;425:468–72.View ArticlePubMedGoogle Scholar
- Tang L, Pu Y, Wong DK, Liu T, Tang H, Xiang T, et al. The hepatitis B virus-associated estrogen receptor alpha (ERalpha) was regulated by microRNA-130a in HepG2.2.15 human hepatocellular carcinoma cells. Acta Biochim Biophys Sin (Shanghai). 2011;43:640–6.View ArticleGoogle Scholar
- Shi KQ, Lin Z, Chen XJ, Song M, Wang YQ, Cai YJ, et al. Hepatocellular carcinoma associated microRNA expression signature: integrated bioinformatics analysis, experimental validation and clinical significance. Oncotarget. 2015;6:25093–108.PubMed CentralView ArticlePubMedGoogle Scholar
- Lan X, Lu G, Yuan C, Mao S, Jiang W, Chen Y, et al. Valproic acid (VPA) inhibits the epithelial-mesenchymal transition in prostate carcinoma via the dual suppression of SMAD4. J Cancer Res Clin Oncol. 2015;142:177–85.View ArticlePubMedGoogle Scholar
- Qiao P, Li G, Bi W, Yang L, Yao L, Wu D. microRNA-34a inhibits epithelial mesenchymal transition in human cholangiocarcinoma by targeting Smad4 through transforming growth factor-beta/Smad pathway. BMC Cancer. 2015;15:469.PubMed CentralView ArticlePubMedGoogle Scholar
- Xia X, Wu W, Huang C, Cen G, Jiang T, Cao J, et al. SMAD4 and its role in pancreatic cancer. Tumour Biol. 2015;36:111–9.View ArticlePubMedGoogle Scholar
- Yang G, Yang X. Smad4-mediated TGF-beta signaling in tumorigenesis. Int J Biol Sci. 2010;6:1–8.PubMed CentralView ArticlePubMedGoogle Scholar
- Hernanda PY, Chen K, Das AM, Sideras K, Wang W, Li J, et al. SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma. Oncogene. 2015;34:5055–68.View ArticlePubMedGoogle Scholar
- Saini S, Arora S, Majid S, Shahryari V, Chen Y, Deng G, et al. Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer. Cancer Prev Res (Phila). 2011;4:1698–709.PubMed CentralView ArticleGoogle Scholar
- Vo DD, Staedel C, Zehnacker L, Benhida R, Darfeuille F, Duca M. Targeting the production of oncogenic microRNAs with multimodal synthetic small molecules. ACS Chem Biol. 2014;9:711–21.View ArticlePubMedGoogle Scholar
- Chen S, Zhu L, Huang J, Cai Y, Lu X, Yang Q, et al. Arsenic trioxide targets miR-125b in glioma cells. Curr Pharm Des. 2014;20:5354–61.View ArticlePubMedGoogle Scholar
- Xia J, Cheng L, Mei C, Ma J, Shi Y, Zeng F, et al. Genistein inhibits cell growth and invasion through regulation of miR-27a in pancreatic cancer cells. Curr Pharm Des. 2014;20:5348–53.View ArticlePubMedGoogle Scholar
- Xia J, Duan Q, Ahmad A, Bao B, Banerjee S, Shi Y, et al. Genistein inhibits cell growth and induces apoptosis through up-regulation of miR-34a in pancreatic cancer cells. Curr Drug Targets. 2012;13:1750–6.View ArticlePubMedGoogle Scholar